Hospital acquired infections
Patients admitted to or visiting hospitals can develop multiple infections, which are known as hospital-acquired infections (HAIs), or, simply, hospital infections. These conditions generally spread within nursing homes, dialysis centres, rehabilitation centres, outpatient surgery centres, and hospitals. Various bacterial, fungal, and viral pathogens can cause hospital infections. Intensive care units are also a common source of HAIs, which can be treated using antimicrobial drugs. Some therapeutic drugs available for these diseases are CAZ AVI, Surotomycin, MK-3415A, and Ceftolozane.
The growing susceptibility of the neonatal population to HAIs and the booming supply of drugs for these conditions is likely to lead to massive growth in the hospital infection therapeutics market in the coming years. Moreover, the lack of skilled nursing staff in healthcare settings, especially in emerging economies, is a key factor making therapeutic drugs more important. In many countries, these factors will offer pharmaceutical companies the opportunity to increase their production capacity in the coming years.
The number of hospitals is also rising worldwide, primarily due to government efforts to make healthcare more accessible. The World Bank reports the number of hospital beds per 1,000 people around the world increased to 2.894 in 2017 from 2.462 in 2005. A higher number of hospital beds means a larger number of hospital patients, which translates into a higher incidence of various HAIs. Ultimately, this will increase the demand for therapeutic drugs in the coming years.
North America has emerged as the hospital infection therapeutics market leader. The reason is the higher ratio of hospitals to the population of the region compared to other parts of the world. The surging population of ageing people in the continent and the increasing number of multi-drug-resistant microbial pathogens are also significant reasons leading to the rising demand for therapeutic drugs. APAC is also witnessing a rising demand for therapeutic drugs, especially in China and India, due to the growing prevalence of HAIs.
[edit] Related articles on Designing Buildings
Featured articles
Check out some of the best features and news from Designing Buildings as well as key stories from around the web.
Electrical contractors need to understand the practical implications.
The real barrier to getting more value from digital technology.
Your guide to The Construction Reset at UKCW Birmingham.
Accommodating the Victorian and Edwardian working woman. Book review.
Rethinking passive fire protection in design
PFP demands the same level of design rigour as structure or services.
38% of Gen Zs feel safe when a fire door is wedged open.
Stunning images from around the world
Shortlist for CIOB’s Art of Building photography competition.
Guidance for conversion of traditional pre-1919 stone buildings.
Industrial heritage in the Ruhr
A marked difference to the fate of industrial landscapes in the UK.
Communities will be able to build their own clean energy.
Why diversity and inclusion matters for SMEs
CIOB’s D&I Charter shows how practical changes can support long-term growth.
Cut electricity bills to power growth
Coalition sends joint letter to the Chancellor.
Comments
[edit] To make a comment about this article, or to suggest changes, click 'Add a comment' above. Separate your comments from any existing comments by inserting a horizontal line.